Research Articles | Page 44 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes Mar 2025 Neoplasia Myelodysplastic Syndromes (MDS)
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms Mar 2025 Archives of Pathology & Laboratory Medicine Myelodysplastic Syndromes (MDS)
Advancing drug development in myelodysplastic syndromes Mar 2025 Blood Advances Myelodysplastic Syndromes (MDS)
Heterogeneity in Health-Related Quality of Life of Patients with Aplastic Anemia: A Latent Profile Analysis Mar 2025 Patient Preference and Adherence Aplastic Anemia
EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial Mar 2025 EJHaem Paroxysmal Nocturnal Hemoglobinuria (PNH)
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia Mar 2025 Blood Cancer Journal Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome Mar 2025 BioDrugs Paroxysmal Nocturnal Hemoglobinuria (PNH)
The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) Mar 2025 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Mar 2025 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study Mar 2025 Blood Cancer Journal Myelodysplastic Syndromes (MDS)